Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenovirus antigen-specific cytotoxic T lymphocyte response
- Molecular classification
- Other (immune response/process mediated by CD8+ T cells, not a molecule)
01
Overview
Adenovirus antigen-specific cytotoxic T lymphocyte response refers to CD8+ T cells recognizing adenoviral peptides presented by MHC class I on infected cells and executing targeted killing. Activation requires TCR engagement with peptide–MHC I and co-stimulation (e.g., CD28 with CD80/CD86), leading to clonal expansion and acquisition of effector functions. CTLs kill primarily by releasing perforin and granzymes from lytic granules at the immunological synapse and can also induce apoptosis via Fas–Fas ligand interactions, while secreting cytokines such as IFN-γ that inhibit viral replication and enhance antigen presentation. In clinical contexts, strong anti-adenoviral CTL responses limit persistence of adenoviral vectors in gene therapy and are leveraged therapeutically via adoptive transfer of adenovirus-specific CTLs to treat refractory adenoviral infections in immunocompromised patients.
- Other names
- Adenovirus-specific CTL responseAdenovirus-specific CD8+ T-cell responseAnti-adenovirus cytotoxic T-cell response
02
Biological functions
Immune response (cell-mediated antiviral immunity by CD8+ T cells)Cytotoxicity/apoptosis induction in infected cells via perforin/granzyme and Fas–FasL pathwaysCytokine production (e.g., IFN-γ, TNF-α) contributing to antiviral effects
03
Disease associations
Infection (host defense against adenovirus; also relevant to adenoviral vector immunity in gene therapy)Other: post-transplant viral complications where adoptive adenovirus-specific CTLs are used therapeutically
04
Safety considerations
Off-target tissue damage and immunopathology from robust CTL responses; liver enzyme elevations and hepatotoxicity can occur with adenoviral vectors, though peak CTL responses may not coincide with peak hepatotoxicityGraft-versus-host disease risk when administering donor-derived virus-specific T cells post-transplant (managed by HLA matching and product selection)Potential for cytokine-related symptoms with strong T-cell activation
05
Biomarkers
Adenovirus-specific tetramer-positive CD8+ T cells (MHC I tetramers for ADV epitopes)Functional cytotoxicity assays against adenovirus-infected targetsCytokine readouts (IFN-γ ELISpot/ICS) to detect ADV-specific T-cell responsesAdenoviral load (PCR) as a clinical efficacy marker in adoptive therapy contexts
Beyond the preview
Go deeper on Adenovirus antigen-specific cytotoxic T lymphocyte response.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adenovirus antigen-specific cytotoxic T lymphocyte response.